Gilead Sciences, Inc.
GILD
#113
Rank
$183.625 B
Marketcap
United States
Country
$148.09
Share price
9.07%
Change (1 day)
29.44%
Change (1 year)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary…
Key Metrics
Trailing P/E
—
Forward P/E
15.26
EPS (TTM)
$-2.70
Forward EPS
$9.89
Price / Book
15.83
EV / EBITDA
14.3x
Beta
0.35
Dividend Yield
2.22%
Return on Equity
-20.68%
Return on Assets
14.09%
Debt / Equity
223.47
Current Ratio
1.26
Gross Margin
79.60%
Operating Margin
33.68%
Net Profit Margin
-10.64%
Free Cash Flow
$9.769B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 17
+2.23%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$29.442B
Latest Net Income$8.510B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Gilead Sciences, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
GILD
No recent news available. Set FINNHUB_API_KEY to enable news.
